Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Managing Immune-Related Adverse Events: A Nursing Perspective
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: May 28, 2021 Expiration: May 27, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Pfizer, Inc. and EMD Serono
person default
Arjun Balar, MD
person default
Kaitlyn Francese, MSN, RN, OCN

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Kaitlyn Francese, MSN, RN, OCN

Senior Nurse Clinician
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Kaitlyn Francese, MSN, RN, OCN, has disclosed that she has received consulting fees from Seattle Genetics/Astellas.
Arjun Balar, MD

Associate Professor of Medicine
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Arjun Balar, MD, has disclosed that he has received consulting fees from AstraZeneca/MedImmune, Bristol-Myers Squibb, Genentech, Immunomedics/Gilead Sciences, Incyte, Istari, Janssen, Merck, Nektar, Pfizer, and Seagen; has received funds for research support paid to his institution from AstraZeneca/MedImmune, Genentech, Immunomedics/Gilead Sciences, Merck, Nektar, and Seagen; and has ownership interest in EpiVax.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to disclose.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to disclose.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for urologists, oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with urothelial carcinoma.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-116-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 28, 2021, through May 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Managing Immune-Related Adverse Events: A Nursing Perspective
  • CME
  • CE

Loading...
Join us for an interactive presentation by Kaitlyn Francese, MSN, RN, OCN, on the nurse’s role in managing immune-related adverse events associated with the use of immune checkpoint inhibitors in urothelial cancer.
person default
Arjun Balar, MD
person default
Kaitlyn Francese, MSN, RN, OCN
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: May 28, 2021 Expiration: May 27, 2022

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

On-demand webcast of live expert webinar on early-stage urothelial carcinoma including upper tract urothelial cancer, from Clinical Care Options (CCO)

Seth P. Lerner, MD
Program Director
Jean Hoffman-Censits, MD Surena Matin, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: October 4, 2021 Expired: October 3, 2022

VESPER trial showed improved PFS and time to progression at 3 years with perioperative dd-MVAC vs gemcitabine + cisplatin in MIBC, from ESMO 2021 by Clinical Care Options (CCO)

Released: September 27, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Pfizer, Inc. and EMD Serono

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue